Straits Times Index
3,313.48 +8.49 (+0.26%) S&P 500
5,303.27 +6.17 (+0.12%) Dow
40,003.59 +134.19 (+0.34%) Nasdaq
16,685.97 -12.33 (-0.07%) Bitcoin USD
66,353.52 -501.91 (-0.75%) CMC Crypto 200
1,356.33 -17.51 (-1.27%)
VERU Oct 2024 1.000 call
| Previous close | 0.7800 |
| Open | 0.6500 |
| Bid | 0.3200 |
| Ask | 0.8700 |
| Strike | 1.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.6500 - 0.7800 |
| Contract range | N/A |
| Volume | |
| Open interest | 245 |
GlobeNewswireVeru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana, as the Principal Investigator f
- GlobeNewswire
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer, will be a Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week, taking place May 21-23, 2024
- GuruFocus.com
Veru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial Recovery
Explore key insights from Veru Inc's Q2 2024 earnings, emphasizing improved financial management and strategic advancements in pharmaceutical development.
